Overview

WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Alcon Research
Treatments:
Ranibizumab